Search Results for: US Rheumatoid Arthritis Treatment Market
Articles
EXECUTIVE INTERVIEW - Cardax Inc: Delivering Nature-Identical Astaxanthin to the Market February 29, 2016
David G. Watumull, President and CEO of Cardax, Inc, discusses the company’s plans to create a new platform for products in the consumer health and pharmaceutical markets based on the delivery of nature-identical astaxanthin.
EXECUTIVE INTERVIEW - Enable Injections: Revolutionizing Treatment With a New Class of Devices January 7, 2016
Michael Hooven, CEO of Enable Injections, discusses his vision for the company and how it intends to create marketleading biologics delivery devices that meet the most pressing needs of pharmaceutical companies while enabling easy patient self-administration for significant cost-savings.
US Demand for Drug Delivery Products to Reach $251 Billion December 28, 2015
US Demand for Drug Delivery Products to Reach $251 Billion Demand for drug delivery products in the US...Caladrius Biosciences Announces Two-Year Study Results December 8, 2015
Caladrius Biosciences, Inc. recently announced the publication of 2-year results from a Phase I clinical study of an autologous Regulatory...DRUG DEVICE MARKET - Joining Forces: Global Markets for Drug-Device Combinations November 19, 2015
Kevin James and Kevin Gainer of BCC Research indicate the development of the market for combination products is closely related to the drug delivery systems sector, which represents a vast area of research and the demand for sophisticated drug delivery devices behind many novel product developments.
Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments March 3, 2015
Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the...REGULATORY GUIDANCE - Staying on Top of FDA Guidance for Industry - Training Webinars Foster Transparency & Collaboration March 2, 2015
Frost & Sullivan recently tuned into three webinars that were considered to be particularly relevant to current hot topics and therapy areas, and then reviews the current trends and needs behind each new or revised guidance document and key insights for potential sponsors.
Five Prime Therapeutics & Bristol-Myers Squibb Announce Exclusive Clinical Collaboration December 2, 2014
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company recently announced they have entered into an exclusive clinical collaboration agreement to...ADVANCED DELIVERY DEVICES - Wearable Bolus Injectors - A New Class of Patient-Friendly Drug Delivery Systems May 6, 2014
Michael D. Hooven, MSME, indicates bolus injectors represent one of the most exciting new opportunities in the field of medical devices, and his company’s focus on developing innovative technology in combination with an intense emphasis on Human Factors has resulted in a system that is unique in a number of ways.
MARKET BRIEF - Latin America Next-Generation Biosimilars Market: Opportunities & Future Growth March 4, 2014
Lucila Rocca, Healthcare Industry Analyst, Frost & Sullivan, indicates the Latin American Biosimilars market will grow at a significant rate in the next 5 years, and the importance of establishing rigorous regulation will stimulate this market growth.
Aptar Presents Latest User-Study Results for Auto-Injector February 12, 2014
Aptar Pharma Prescription Division will present and discuss the latest data from a number of user studies carried out with...MARKET BRIEF - Controlled Release Technologies: Advancing Toward Targeting Therapeutics June 10, 2013
Frost & Sullivan Analyst Cecilia Van Cauwenberghe, MS, reviews a few recent innovative approaches to controlled release technologies with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
ADVANCED DELIVERY DEVICES - Important Considerations in the Delivery of Large-Volume & Viscous Drugs April 30, 2013
Kevin Cancelliere, MS, believes that as the trend toward self-administration continues, the need for careful consideration of primary container design, interaction with the drug product, method of administration, and end-user needs becomes even more critical.
Novartis Expects 14 New Blockbusters November 8, 2012
Novartis recently provided an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into...Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan October 25, 2012
Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of...CELL & GENE THERAPY - It’s Time to Build Infrastructure to Handle the Coming Surge April 30, 2024
Fran Gregory says the complexities and innovations associated with the production of cell and gene therapies also necessitates a shift in infrastructure, which will affect manufacturers, distributors, and providers. From development, manufacturing, storage, and delivery to patients; each step in the process requires forging a new path.
Incannex Provides Update on Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea December 6, 2023
Incannex Healthcare Inc. recently provided the following update on its proprietary IHL-42X drug candidate. Obstructive sleep apnea (OSA) is characterized...IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs May 1, 2023
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
VBL Therapeutics & Notable Labs Announce Definitive Merger Agreement February 23, 2023
VBL Therapeutics and Notable Labs, Inc. recently announced they have entered into a definitive merger agreement. The combined company will...Alvotech & Bioventure Announce Approval of AVT02 (Adalimumab) as Simlandi in Saudi Arabia January 24, 2023
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure….
